Ashish Kacholia’s stock, specializing in the manufacturing of specialty chemicals, jumps 18 percent upon declaring Q3 results and generating profit with a 168 percent rise Year on Year (YoY)
Price action
With a market capitalization of Rs. 8,300 crores on Wednesday, the shares of Ami Organics Limited jumped 18 percent making a high of Rs. 2,215 per share compared to its previous closing price of Rs. 1,881.85 per share.
What Happened
Ami Organics Limited specializing in the manufacturing of specialty chemicals has announced its Q3FY25 results. Its Revenue from Operations grew by 65 percent YoY from Rs. 166 Crores in Q3FY24 to Rs. 275 Crores in Q3FY25 and it grew by 11.3 percent QoQ from Rs. 247 Crores in Q2FY25 to Rs. 275 Crores in Q3FY25.
Its Net Profit rose 155 percent YoY from Rs. 17.8 Crores in Q3FY24 to Rs. 45.4 Crores in Q3FY25 and it rose by 20.7 percent QoQ from Rs. 37.6 Crores in Q2FY25 to Rs. 45.4 Crores in Q3FY25.
Ace Investor
Ace Investor Ashish Kacholia holds a stake of 1.84 percent in the company which consists of 7,54,974 equity shares as of December, 2024
Ami Organics — At a Glance
Ami Organics is a leading Research and Development manufacturer of Specialty Chemicals, that focuses on the development and manufacturing of Advanced Pharmaceutical Intermediates and Specialty Chemicals, it Serves diverse end-use industries including Pharmaceuticals, Cosmetics, Fine Chemicals, Semiconductor, Battery Chemicals, among others.
Earnings & Business Highlights (Q3FY25)
The company’s EBITA is up by 159 percent YoY to Rs. 68.7 crores, EBITDA Margin to 25 percent and PAT is up by 155 percent YoY to Rs. 45.4 crores, PAT Margin to 16.5 percent up 582 bps YoY and 130 bps QoQ, along with it company’s export revenue for the quarter is 76 percent and Domestic business at 24 percent.
Revenue Segments
The company’s Revenue is driven by two segments of which 79 percent of revenue is from Advanced Pharmaceutical Intermediates and 21 percent of revenue from Specialty Chemicals.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any los
